
Topic
GLP-1
Semaglutide, tirzepatide, oral GLP-1 candidates, supply capacity, coverage pressure, and the access systems around metabolic drugs.

Pricing & Access· May 31, 2026 · 15 min read
By Ran Chen#GLP-1#Medicare Part D#Prior Authorization

Pricing & Access· May 31, 2026 · 13 min read
Medicare GLP-1 Bridge patient ineligibility traps
By Ran Chen#Medicare Part D#GLP-1#Prior Authorization

Pricing & Access· May 31, 2026 · 9 min read
Oral GLP-1 launch access checklist: payer team readiness before approval
By Ran Chen#GLP-1#Oral GLP-1#Payer Policy

Policy· May 30, 2026 · 11 min read
Medicare GLP-1 Bridge program guide for $50 obesity drug access
By Ran Chen#GLP-1#Medicare Part D#Drug Pricing

Pricing & Access· May 29, 2026 · 12 min read
Foundayo coverage guide: orforglipron access, pricing, and PA criteria
By Ran Chen#GLP-1#Obesity#Prior Authorization

Pipeline· May 26, 2026 · 8 min read
CagriSema pre-approval evidence review for obesity access teams
By Ran Chen#GLP-1#Amylin Analog#Obesity

Approvals· May 26, 2026 · 8 min read
Novel FDA drug approvals Q1-Q2 2026: the fifteen drugs and their formulary implications
By Ran Chen#FDA Approval#Novel Drug Approvals#GLP-1

Pricing & Access· May 23, 2026 · 9 min read
Trulicity coverage guide: formulary tiers, prior authorization, and patient assistance
By Ran Chen#GLP-1#Coverage Access#Prior Authorization

Pricing & Access· May 20, 2026 · 10 min read
Mounjaro vs Zepbound: label, access, and payer coverage compared
By Ran Chen#GLP-1#Coverage Access#Prior Authorization

Pricing & Access· May 16, 2026 · 10 min read
Wegovy vs Zepbound: label, access, and payer coverage compared
By Ran Chen#GLP-1#Prior Authorization#Payer Policy